新一代蛋白質療法

本報告已在2011年12月21日停止出版。

簡介

目錄

Abstract

Introduction

Although protein-based therapeutics were seen as a risky and diffi cult fi eld of endeavor, the biopharmaceutical industry's persistent pursuit of such agents created a multi-billion-dollar marketplace and a host of life-saving treatments. Now, as fi rst-generation drugs face patent expiry, the industry is pursuing technological and commercial opportunities that it hopes will yield the next generation of protein-based drugs, improving patient care and expanding market share.

Get the Answers You Need to Shape Your Strategy

Companies are developing technologies that will remodel recombinant protein and MAb therapeutics into next-generation drugs. What opportunities are being pursued for improving protein therapeutics? How will next-generation drugs improve upon their predecessors? Targeting protein therapeutics to reduce adverse side effects is an important goal and includes the creation of new classes of fusion proteins. Which companies are developing leading-edge technologies? What other advantages do targeted therapeutics hold? Researchers have developed promising new techniques for conjugating MAbs to various payloads, such as adding cytotoxic agents or radioisotopes to protein-based drugs. What are the advantages of these new protein conjugation techniques? Which companies lead the field? Demand for protein therapeutics grows each year, but manufacturing therapeutic proteins remains expensive and time-consuming. How are companies reducing cost and the time needed to produce recombinant proteins? Which methods are most promising?

Table of Contents

• Executive Summary
• Strategic Considerations
• Stakeholder Implications
• Introduction
• Current Landscape of Recombinant Protein and MAb Therapeutics
• The Protein Therapeutic Market
• Key Players in the Protein Therapeutic Marketplace
• First-Generation Protein Therapeutics
• Sidebar: Monoclonal Antibodies: An Important Class of Protein Therapeutics
• The Changing Landscape: Opportunities for Second-Generation Protein Therapeutics
• New Approaches in Developing Next-Generation Protein Therapeutics
• Increasing Affinity
• Targeting Therapeutics with Fusion Proteins
• Improving Potency Through Cytotoxicity
• Engineering Constant Regions
• Conjugated Protein Therapeutics .
• Reducing Immunogenicity
• Protein Production
• Corporate Profiles
• Affibody
• Ambrx
• Chromos Molecular Systems
• EvoGenix
• Seattle Genetics
• Trellis Bioscience
• Outlook for Protein Therapeutics

Tables

• 1. Marketed MAb Therapeutics
• 2. Recent Acquisitions in Proteins and MAbs
• 3. Select Companies in Protein/MAb Engineering/Production

Figures

• 1. Protein Therapeutic Market, 2005 and 2010
  • A. Structural Components of an IgG Antibody
  • B. Antibodies: From Mouse to Human

相關商品

抗體和免疫相關市場調查報告書

大腸癌、血管增生、抗體分析
Triple Analysis: Colorectal Cancer, Angiogenesis and Antibodies
價格 : US $ 5175
出版日期 : 2012年01月

白血病、血管增生、抗體：藥劑開發策略分析
Triple Analysis: Leukemia, Angiogenesis and Antibodies
價格 : US $ 5175
出版日期 : 2012年01月

淋巴癌、血管增生、抗體：藥劑開發策略分析
Triple Analysis: Lymphoma, Angiogenesis and Antibodies
價格 : US $ 5175
出版日期 : 2012年01月

Decision Resources, Inc.發行的生物科技相關市場調查報告書

以生物標記來預測自體免疫疾病生物療法的反應

Special Report: Use of Biomarkers to Predict Response to Biologics Therapy in Autoimmune Diseases

價格 : US $ 9200

出版日期 : 2011年06月

成為下一波一鳴驚人藥物的新一代治療用抗體的尋求

Pursuing Next-Generation Therapeutic Antibodies as the Next Source of Blockbuster Drugs

價格 : US $ 4600

出版日期 : 2011年06月

探索讓個人化醫療進化的資訊技術工具

Exploiting Information Technology Tools to Advance Personalized Medicine

價格 : US $ 4600

出版日期 : 2011年05月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!